NASDAQ:AVDLAvadel Pharmaceuticals Stock Price, Forecast & News

Avadel Pharmaceuticals' stock was trading at $7.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AVDL stock has increased by 1.1% and is now trading at $8.08. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avadel Pharmaceuticals.

Avadel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Avadel Pharmaceuticals.

Avadel Pharmaceuticals PLC (NASDAQ:AVDL) posted its earnings results on Monday, May, 11th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.27) by $0.25. The company earned $12.24 million during the quarter, compared to analyst estimates of $10.25 million. View Avadel Pharmaceuticals' earnings history.

Avadel Pharmaceuticals issued an update on its first quarter 2020 Pre-Market earnings guidance on Thursday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $10 million, compared to the consensus revenue estimate of $8.35 million.

6 equities research analysts have issued 1-year target prices for Avadel Pharmaceuticals' shares. Their forecasts range from $6.00 to $18.00. On average, they expect Avadel Pharmaceuticals' stock price to reach $11.92 in the next twelve months. This suggests a possible upside of 47.5% from the stock's current price. View analysts' price targets for Avadel Pharmaceuticals.

Headlines about AVDL stock have trended very negative this week, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Avadel Pharmaceuticals earned a news sentiment score of -3.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutAvadel Pharmaceuticals.

Avadel Pharmaceuticals saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 6,500,000 shares, an increase of 47.7% from the April 15th total of 4,400,000 shares. Based on an average daily volume of 730,600 shares, the short-interest ratio is presently 8.9 days. Currently, 18.8% of the shares of the stock are sold short. View Avadel Pharmaceuticals' Current Options Chain.

Some companies that are related to Avadel Pharmaceuticals include Revance Therapeutics (RVNC), Esperion Therapeutics (ESPR), Myovant Sciences (MYOV), Odonate Therapeutics (ODT), Aimmune Therapeutics (AIMT), Nabriva Therapeutics (NBRV), Phibro Animal Health (PAHC), Enanta Pharmaceuticals (ENTA), Applied Therapeutics (APLT), Rocket Pharmaceuticals (RCKT), INDIVIOR PLC/S (INVVY), MacroGenics (MGNX), BioXcel Therapeutics (BTAI), Athenex (ATNX) and Stoke Therapeutics (STOK). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Chaarat Gold (CGH), Associated British Foods (ABF), AMC Entertainment (AMC), Ciena (CIEN), Apollo Global Management (APO), First Data (FDC) and China Unicom (Hong Kong) (CHU).

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Avadel Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (9.55%), Cowen AND Company LLC (4.05%), VR Adviser LLC (2.82%), Invesco Ltd. (1.96%), Tekla Capital Management LLC (1.51%) and Driehaus Capital Management LLC (1.31%). Company insiders that own Avadel Pharmaceuticals stock include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, James E Flynn, Michael S Anderson and Sandra L Hatten. View institutional ownership trends for Avadel Pharmaceuticals.

AVDL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Tekla Capital Management LLC, UBS Group AG, and Investors Asset Management of Georgia Inc. GA ADV. View insider buying and selling activity for Avadel Pharmaceuticals.

AVDL stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Cowen AND Company LLC, VR Adviser LLC, Invesco Ltd., Driehaus Capital Management LLC, Ghost Tree Capital LLC, Arlington Capital Management Inc., and Bailard Inc.. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, and Michael S Anderson. View insider buying and selling activity for Avadel Pharmaceuticals.

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AVDL stock can currently be purchased for approximately $8.08.

Avadel Pharmaceuticals has a market capitalization of $302.60 million and generates $59.22 million in revenue each year. The company earns $-33,230,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Avadel Pharmaceuticals employs 144 workers across the globe.

The official website for Avadel Pharmaceuticals is www.avadel.com.

Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 353-1485-1200 or via email at [email protected]